An interventional study of COGNITIVE BEHAVIORAL THERAPY in IBS - Irritable Bowel Syndrome, sponsored by University of California, Los Angeles. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment
Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles — 2 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · University of California, Los Angeles.
Among the 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 11 with no phase, and was the 13th registered.
1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.
Browse Irritable Bowel Syndrome studies →2 of the 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18–50
By country, each count listing its studies:
Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2021.
This study's enrollment of 65 is close to the median of 70 across 900 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 58 across the 11 interventional studies, 187 across the 4 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cognitive Behavioral Therapy (CBT) is the most well researched and most effective treatment for IBS targeting the brain-gut-microbiome (BGM) axis, and preliminary data show that this therapeutic effect is associated with a reduction of brainstem connectivity with other brain networks.
The increased prevalence of IBS in women, the higher rate of comorbid non-GI pain conditions, as well as the higher prevalence in female IBS of increased sensitivity to a variety of internal and external stimuli (multisensory sensitivity) suggest the presence of important sex differences in some of these BGM mechanisms.
Research performed by UCLA SCOR during previous funding has established an increased responsiveness of the CRF-Locus Coeruleus (LCC) system in female IBS subjects, suggesting that this central noradrenergic brainstem system plays an important role in IBS pathophysiology.
In addition, the study team's earlier research has begun to identify clinical, functional and structural brain mechanisms that may underlie these sex effects. Based on the preliminary data, the overall goal of this project is to use CBT as a probe to study the relationship between specific disease-related alterations of the brain, the gut microbiome, and symptomatic outcome, and identify the role of sex differences in these relationships. Investigators will study male and female IBS patients before and after CBT using the advanced neuroimaging and microbiome technologies of the overall SCOR.
A total of 150 adult IBS participants will be completed in years 1-4 of the proposed studies. These will be 50 males, 50 premenopausal females in the treatment arm (Cognitive behavioral therapy: CBT) and 50 in 'usual care' arm, all bowel habit subtypes.
Screening V1: All subjects will have a pre-screening using a study specific IRB approved prescreening tool (15-20 minutes). lf eligible and interested, the study team will send the ICF via email to the subject and then study team will review the ICF with the subject to determine understanding of study participation and risks/benefits. Subjects will sign and return to the coordinator by electronic/scan/fax methods. The study team will then send participants a short link of preliminary questionnaires via survey Monkey to further determine eligibility for participation and assist the clinician in obtaining accurate medical history as well as assess any risk factors of participation. When determined to be eligible, the study team will set up a video/zoom /phone meeting to complete the initial screening visit/medical and psychological history taking. This will take about 1.5 hour.
Subjects will come to the OCNSR center to complete the study screening, including a physical exam by the RN and RN/NP or MD. Upon arrival, they will date and sign the informed consent and have time to ask any questions. The physical exam will include vital signs, height, weight, and a ROS (review of systems). There will be a single blood sample taken of about 2 teaspoons to determine menstrual cycle (females) and if needed, there may be additional blood (about 1 tablespoon) for IBS-diarrhea or mixed predominance to rule out any other gastrointestinal disease similar to IBS symptoms. Subjects will be given sample collection items to take home for stool and diet diary collection. The stool sample will be collected when they return for the scheduled MRI within 1-3 weeks of screening. They will be given two unique de-identified online Survey Monkey links to complete before the MRI visit. One link is a Diet History Questionnaires (VioScreen) and the other is a group of questionnaires asking about symptoms (IBS), mood and general health and wellbeing. This visit will take about 1.5-2 hours.
MRI V2: Brain and Brainstem Data Acquisition: All participants will undergo a 70 minute structural, resting state, DTI and brain stem MRI scanning session. All subjects will be imaged on a Siemens 3 Tesla Prisma scanner housed at the UCLA Ahmanson-Lovelace Brain Mapping Center (ALBMC). Subjects will complete several state anxiety and symptom-measuring questionnaires upon arrival . Females will need to do daily urine test at home to identify their menstrual phase. When arriving to MRI they will give a urine sample for pregnancy testing and will be excluded if pregnant. A single blood sample will be collected via venipuncture for hormones, cell methylation and pro inflammatory cytokines (15-20 ccs). Subjects will return with their diet diary, stool and saliva (female) sample collections and have all samples reviewed by study coordinator, for viability and collection accuracy.
Scanning will follow parameters of the HBC (Human Brain Connectome) project with anterior and posterior views for each scan. They will have the structural MP Rage (gray matter imaging) scan (time \~14.5 minutes) and subjects can watch a movie of their choice during this scan.
Following this is 2 RSN (resting state) functional scan (total time \~12 minutes). Instructions verbatim are given to subject during the RSN to rest, relax and focus on the crosshair displayed on mirrored screen reflected on the head coil without going to sleep. Following the resting state scan the subject will be asked if they had any pain or discomfort anywhere that may have distracted the subject during the functional resting state and this will be documented on a subject chart.
The next scan is the DTI (diffusion tensor imaging) lasting approximately 10 minutes. Subjects can watch a movie of their choice during this scan.
This visit will take no more than 1.5-2 hours.
Subjects will then be randomized to CBT (66.5 % chance) or usual care (33.5 % chance). The CBT is described below. If usual care, the subject will not have any restrictions on subjects except that the study team will ask subjects not to start new therapies for IBS or new medicines unless it is deemed necessary by their PCP.
CBT: This structured educational and skills based intervention is carried out via internet instruction and individual practice. Subjects will be asked to log into the CBT site once per week for 8-10 weeks with each session lasting between 20 and 40 minutes. The content has been validated in a randomized internet-based CBT trial for IBS. The intervention does not entail any direct therapist contact or interaction with other patients or study participants. The intervention is hosted by Mahana Therapeutics Inc. (named Parallel TM) who is contracted by UCLA to provide the intervention. Following enrollment, each subject will receive a secure login for accessing the CBT site and no personally identifying information will be asked for or passed along to the site or Mahana Therapeutics. During the 8 week intervention period subjects will be contacted by a study coordinator for follow-up should they stop logging in to the web site and they will be able to contact a study coordinator with questions regarding the intervention, website access, etc.
A responder will be defined as a subject with IBS-SSS score change of ≥50 from baseline to end of treatment and corresponds to a clinically meaningful change in symptoms. Participants assigned to the Usual Care condition will have the same questionnaire, neuroimaging, biological and symptom assessments as those in CBT but will not have any specific intervention from the project.
There will be a short mid study SM questionnaire link to complete related to symptoms. After 8-10 weeks of CBT (within 2-3 weeks of completion) they will return for a post-CBT MRI visit identical to description above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any other condition that the investigator believes would jeopardize the safety or rights of the subject or would render the subject unable to comply with the study protocol or make use of acquired data non-analyzable.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the "Cognitive Behavioral Treatment" Arm will undergo 8-10 weeks of remote cognitive behavioral therapy. Subjects will complete modules on their phones and will be monitored by study coordinators for support and treatment completion.
Behavioral: COGNITIVE BEHAVIORAL THERAPY
Subjects in the "Usual Care" Arm will undergo 8-10 weeks of continued lifestyle. Subjects will be asked to report any new medications or lifestyle changes to study coordinators throughout the 8-10 weeks.
8-10 week self directed on line CBT program approved by FDA
Degree of Connectivity Between Brainstem Nuclei and the Salience, Emotional Arousal and Sensorimotor Networks Brain Networks.
ROI (Region of Interest)-to-ROI connection pairs from resting-state fMRI data were computed and extracted to test functional connectivity between brainstem nuclei (Bstem) and the salience (SN), emotional arousal (EAN), and sensorimotor (SMN) networks. Participant-level composite scores were calculated by averaging connectivity values (Z transformed R values) across all ROI pairs within each unique network target for a total of 10 intrinsic and extrinsic network connections. Pre to post treatment mean changes in these composite scores were tested for differences between the usual care and CBT treatment groups using apriori contrast analyses with in the frame work of a linear mixed effects model , i.e. (CBT BL - CBT Post) - (UsualCare BL - UsualCare Post). Results are reported as the estimate marginal mean difference (estimate) and standard error (SE), the t statistic, the probability (p) and the 5% False Discovery Rate corrected p value (q) , and Cohen's effect size D with 95% CIs.
Time frame: Before and after completion of 10 weeks of intervention or usual care.
Irritable Bowel Symptom Severity Scale (IBSSS)
The IBSSS is a validated composite symptom measure for severity of IBS symptoms. It will be used to determine treatment responder (\>50 point change pre to post treatment). Outcome measures the number of patients imporved in each groups (e.g. number of patients who had a \>50pts change on IBS-SSS).
Time frame: Before and after completion of 10 weeks of intervention or usual care.
Abundance of Clostridiales Taxa
Stool sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of Clostridiales determined.
Time frame: Through study completion, an average of 2 years 11 months
Level of Tryptophan Metabolites
Plasma sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of tryptophan metabolites determined.
Time frame: Through study completion, an average of 2 years 11 months
KYN/TR Ratio.
Plasma samples taken pre and post treatment will be processed according to standard laboratory procedures and KYN/TR ration determined.
Time frame: Through study completion, an average of 2 years 11 months
| Milestone | Cognitive Behavioral Treatment Arm | Usual Care Arm |
|---|---|---|
| Started | 45 | 20 |
| Completed | 37 | 18 |
| Not completed | 8 | 2 |
ROI (Region of Interest)-to-ROI connection pairs from resting-state fMRI data were computed and extracted to test functional connectivity between brainstem nuclei (Bstem) and the salience (SN), emotional arousal (EAN), and sensorimotor (SMN) networks. Participant-level composite scores were calculated by averaging connectivity values (Z transformed R values) across all ROI pairs within each unique network target for a total of 10 intrinsic and extrinsic network connections. Pre to post treatment mean changes in these composite scores were tested for differences between the usual care and CBT treatment groups using apriori contrast analyses with in the frame work of a linear mixed effects model , i.e. (CBT BL - CBT Post) - (UsualCare BL - UsualCare Post). Results are reported as the estimate marginal mean difference (estimate) and standard error (SE), the t statistic, the probability (p) and the 5% False Discovery Rate corrected p value (q) , and Cohen's effect size D with 95% CIs.
| Z transformed R values | Cognitive Behavioral Treatment Arm | Usual Care Arm |
|---|---|---|
| Bstem_to_EAN | -0.02 ± 0.01 | 0.03 ± 0.01 |
| EAN_to_SN | -0.02 ± 0.01 | 0.05 ± 0.02 |
| Bstem_to_Bstem | -0.01 ± 0.01 | 0.06 ± 0.02 |
| EAN_to_EAN | -0.01 ± 0.01 | 0.01 ± 0.02 |
| EAN_to_SMN | -0.01 ± 0.01 | -0.02 ± 0.02 |
| SMN_to_SMN | 0.01 ± 0.01 | 0.01 ± 0.02 |
| SMN_to_SN | 0.01 ± 0.01 | 0.01 ± 0.01 |
| Bstem_to_SN | -0.01 ± 0.01 | 0.01 ± 0.01 |
| SN_to_SN | 0.01 ± 0.02 | 0.01 ± 0.03 |
| Bstem_to_SMN | 0.00 ± 0.01 | 0.01 ± 0.02 |
The IBSSS is a validated composite symptom measure for severity of IBS symptoms. It will be used to determine treatment responder (\>50 point change pre to post treatment). Outcome measures the number of patients imporved in each groups (e.g. number of patients who had a \>50pts change on IBS-SSS).
| Participants | Cognitive Behavioral Treatment Arm | Usual Care Arm |
|---|---|---|
| Irritable Bowel Symptom Severity Scale (IBSSS) | 19 | 4 |
Stool sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of Clostridiales determined.
Results for this outcome have not been posted.
Plasma sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of tryptophan metabolites determined.
Results for this outcome have not been posted.
Plasma samples taken pre and post treatment will be processed according to standard laboratory procedures and KYN/TR ration determined.
Results for this outcome have not been posted.
Collected over Through study completion, an average of 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cognitive Behavioral Treatment Arm | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) |
| Usual Care Arm | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Age, Categorical(Participants) | Cognitive Behavioral Treatment Arm | Usual Care Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 37 | 18 | 55 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Cognitive Behavioral Treatment Arm | Usual Care Arm | Total |
|---|---|---|---|
| Mean | 28.19 ± 6.02 | 28.39 ± 8.41 | 28.25 ± 6.89 |
| Sex: Female, Male(Participants) | Cognitive Behavioral Treatment Arm | Usual Care Arm | Total |
|---|---|---|---|
| Female | 28 | 14 | 42 |
| Male | 9 | 4 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Cognitive Behavioral Treatment Arm | Usual Care Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 33 | 13 | 46 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cognitive Behavioral Treatment Arm | Usual Care Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 5 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 19 | 9 | 28 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 4 | 0 | 4 |
| Region of Enrollment(participants) | Cognitive Behavioral Treatment Arm | Usual Care Arm | Total |
|---|---|---|---|
| United States | 45 | 20 | 65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Nov 2024, 34 months.
Results were first posted in Nov 2026, 1 year 11 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2024 → Nov 2024 and completion Jan 2025 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.
Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →